Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced CRC and KRAS G12D Inhibitor in Advanced ...
CStone Pharmaceuticals (CStone, HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and ...
Incyte (Nasdaq:INCY) today announced that results from Phase 1 proof-of-concept studies of INCA33890, a promising TGFβR2×PD-1-directed bispecific antibody, and INCB161734, a novel, selective and ...
Impact of time to relapse (TTR) and metastasectomy (MTS) on survival in leiomyosarcoma (LMS): A CanSaRCC study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does ...
In terms of safety, among participants receiving monotherapy and combination therapy, 19 (27.9%) and 26 (35.6%) reported treatment-related adverse events (TRAEs) of Grade 3 or higher, respectively.
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced results from the Phase III HARMONi ...
Monotherapy of envafolimab in patients with high tumor mutational burden advanced solid tumors: Results from a phase II clinical trial. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
Incyte (INCY) announced the first clinical data evaluating its TGFbetaR2PD-1 bispecific antibody for patients with microsatellite stable, MSS, ...
Golidocitinib combined with PD-1 antibodies achieved a 44.3% response rate in NSCLC patients post anti-PD-1 therapy progression. The combination therapy showed a complete response rate of 23.9% and a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback